Literature DB >> 20484021

CXCL12 (SDF-1)/CXCR4 pathway in cancer.

Beverly A Teicher1, Simon P Fricker.   

Abstract

Chemokines, small proinflammatory chemoattractant cytokines that bind to specific G-protein-coupled seven-span transmembrane receptors, are major regulators of cell trafficking and adhesion. The chemokine CXCL12 [stromal cell-derived factor-1 (SDF-1)] binds primarily to CXC receptor 4 (CXCR4; CD184). The binding of CXCL12 to CXCR4 induces intracellular signaling through several divergent pathways initiating signals related to chemotaxis, cell survival and/or proliferation, increase in intracellular calcium, and gene transcription. CXCR4 is expressed on multiple cell types including lymphocytes, hematopoietic stem cells, endothelial and epithelial cells, and cancer cells. The CXCL12/CXCR4 axis is involved in tumor progression, angiogenesis, metastasis, and survival. This pathway is a target for therapeutics that can block the CXCL12/CXCR4 interaction or inhibit downstream intracellular signaling. Copyright 2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20484021     DOI: 10.1158/1078-0432.CCR-09-2329

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  542 in total

1.  In vivo Evaluation of an Engineered Cyclotide as Specific CXCR4 Imaging Reagent.

Authors:  Wojciech G Lesniak; Teshome Aboye; Samit Chatterjee; Julio A Camarero; Sridhar Nimmagadda
Journal:  Chemistry       Date:  2017-08-03       Impact factor: 5.236

2.  Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists.

Authors:  Beili Wu; Ellen Y T Chien; Clifford D Mol; Gustavo Fenalti; Wei Liu; Vsevolod Katritch; Ruben Abagyan; Alexei Brooun; Peter Wells; F Christopher Bi; Damon J Hamel; Peter Kuhn; Tracy M Handel; Vadim Cherezov; Raymond C Stevens
Journal:  Science       Date:  2010-10-07       Impact factor: 47.728

3.  Structural determinants of ubiquitin-CXC chemokine receptor 4 interaction.

Authors:  Vikas Saini; Adriano Marchese; Wei-Jen Tang; Matthias Majetschak
Journal:  J Biol Chem       Date:  2011-10-28       Impact factor: 5.157

Review 4.  Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4).

Authors:  Won-Tak Choi; Srinivas Duggineni; Yan Xu; Ziwei Huang; Jing An
Journal:  J Med Chem       Date:  2011-12-02       Impact factor: 7.446

Review 5.  CXCR4-based imaging agents.

Authors:  Lauren E Woodard; Sridhar Nimmagadda
Journal:  J Nucl Med       Date:  2011-11       Impact factor: 10.057

6.  [68Ga-pentixafor PET: clinical molecular imaging of chemokine receptor CXCR4 expression in multiple myeloma].

Authors:  M Avanesov; M Karul; T Derlin
Journal:  Radiologe       Date:  2015-10       Impact factor: 0.635

Review 7.  Bone metastasis and the metastatic niche.

Authors:  Guangwen Ren; Mark Esposito; Yibin Kang
Journal:  J Mol Med (Berl)       Date:  2015-08-15       Impact factor: 4.599

8.  Blocking SDF-1α/CXCR4 downregulates PDGF-B and inhibits bone marrow-derived pericyte differentiation and tumor vascular expansion in Ewing tumors.

Authors:  Randala Hamdan; Zhichao Zhou; Eugenie S Kleinerman
Journal:  Mol Cancer Ther       Date:  2013-11-26       Impact factor: 6.261

9.  CoCl2 increases the expression of hypoxic markers HIF-1α, VEGF and CXCR4 in breast cancer MCF-7 cells.

Authors:  Qing Li; Rong Ma; Mei Zhang
Journal:  Oncol Lett       Date:  2017-11-08       Impact factor: 2.967

10.  Silymarin inhibited DU145 cells by activating SLIT2 protein and suppressing expression of CXCR4.

Authors:  Sedat Kacar; Nuriye Ezgi Bektur Aykanat; Varol Sahinturk
Journal:  Med Oncol       Date:  2020-02-15       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.